Articles from Autobahn Therapeutics

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, and Will Stratton, SVP Corporate Development, Strategy, and Planning, will participate in the 2025 Jefferies London Healthcare Conference being held November 17-20, 2025, in London, UK.

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that management will participate in the following upcoming investor conferences in September:

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Will Stratton, VP, Corporate Development, Strategy, and Planning, will participate in Evercore’s Emerging Private Biotech Conference being held July 13-15, 2025, in Newport, RI.

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference on Tuesday, June 3, 2025, in New York.

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the clinical results from its completed Phase 1 trial of ABX-002 at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27-30, 2025, in Scottsdale, AZ. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance the CNS benefits of thyroid hormone biology for patients suffering from major depressive disorder (MDD), bipolar disorder depression, and other affective illnesses.

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipolar depression and will inform Autobahn’s further clinical development strategy.

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the following upcoming investor conferences:

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) to support initiation of a Phase 2 trial of ABX-002 as an adjunctive treatment for patients with bipolar depression. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance the CNS benefits of thyroid hormone biology and drug concentrations directly in the brain.

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced initiation of AMPLIFY, a Phase 2 clinical trial evaluating ABX-002 as an adjunctive treatment for adults with major depressive disorder (MDD). ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance the CNS benefits of thyroid hormone biology and drug concentrations directly in the brain, for greater potency, efficacy and safety. In a completed Phase 1 trial of ABX-002, ABX-002 demonstrated clinical evidence of CNS target engagement consistent with brain-activating thyroid effects and was well-tolerated, with no serious adverse events observed.

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the following upcoming investor conferences in September:

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the closing of an oversubscribed $100 million Series C financing led by Newpath Partners, with participation from new investors Canaan Partners, Monograph Capital, and Insight Partners. All of the company’s existing investors participated in the round, including founding investors ARCH Venture Partners and Blue Owl Healthcare Opportunities, as well as BVF Partners, Invus, Samsara BioCapital, Biogen, Bristol Myers Squibb, Pfizer Ventures, Section 32, Alexandria Venture Investments and GT Healthcare Capital Partners.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Leerink Partners Biopharma Private Company Connect on Wednesday, June 26, 2024.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference in New York on Tuesday, June 4, 2024.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:45 p.m. ET.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024, at 3:30 p.m. ET.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in two upcoming investor conferences:

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Stifel 2023 Healthcare Conference in New York on Wednesday, November 15, 2023, at 12:40 p.m. ET.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced positive topline results from a first-in-human Phase 1 clinical study assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of escalating doses of ABX-002 in healthy volunteers. ABX-002, a potent and selective thyroid hormone beta receptor (TRβ) agonist, is an orally administered small molecule being evaluated as a potential adjunctive treatment for people with major depressive disorder (MDD).

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform and strategies driven by clinical precedence and validated biology to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present at the following upcoming investor conferences:

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced progress with its lead clinical candidate, ABX-002, and early pipeline advancements. In addition, the company further strengthened its senior leadership team with the promotion of Gudarz Davar, M.D., to Executive Vice President, Head of Research and Development. Dr. Davar is an accomplished neurologist and neuroscientist with three decades of corporate and academic leadership in neuroscience research.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on Monday, September 11, 2023, at 12:55 p.m. ET.

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by CNS disorders, today announced that it has initiated the multiple ascending dose (MAD) portion of its Phase 1 study of ABX-002 in healthy subjects. Autobahn is evaluating ABX-002, a potent and selective thyroid receptor beta (TRβ)-selective agonist, as a potential adjunctive treatment for people with major depressive disorder (MDD).

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that Kevin Finney, chief executive officer, and Gudarz Davar, M.D., chief medical officer, will present a company overview at the Stifel 2023 Virtual CNS Days on Tuesday, March 28, 2023 at 3:30 p.m. ET.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the initiation of dosing in the company’s Phase 1 clinical trial of ABX-002 in healthy volunteers. ABX-002 is a potent and selective, brain-boosting thyroid receptor beta (TRβ) agonist that Autobahn is evaluating as a potential adjunctive treatment for people with major depressive disorder (MDD) who are experiencing an inadequate response to their antidepressant.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the closing of a $32.7 million financing to support the company’s continued commitment to transforming the treatment of CNS disorders, led by a strategic prioritization on addressing treatment-resistant depression (TRD). Current shareholders ARCH Venture Partners, Cowen Healthcare Investments, BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments and GT Healthcare all participated in the round.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced new preclinical data supporting the potential of its novel CNS-directed thyromimetic program to induce remyelination in models where loss of myelin is a key driver of disease. The results highlight the utility of Autobahn’s lead program, ABX-002, in demyelinating diseases. ABX-002 is an amide prodrug which readily crosses the blood-brain barrier and is then cleaved by fatty acid amide hydrolase resulting in enhanced delivery of the active metabolite to the brain. The data will be presented by collaborators from the University of Wisconsin and the University of Colorado Anschutz Medical Campus at the Myelin Gordon Research Conference and the Cold Spring Harbor Lab Glia Meeting, respectively.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced new preclinical data highlighting the company’s thyroid hormone-targeted approach to precisely deliver tailored therapeutics to the brain for the treatment of a range of CNS disorders. The data will be presented during two poster sessions at the Society for Neuroscience Annual Meeting, being held virtually from November 8-11, 2021. Posters will be made available to registered attendees online beginning on November 3, 2021.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that the company has strengthened its leadership team with the appointment of Gudarz Davar, M.D., as executive vice president, chief medical officer and the promotion of Chan Beals, M.D., Ph.D., to senior vice president, chief of translational medicine.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the company’s investigational product candidate, ABX-002, for the treatment of patients with X-linked adrenoleukodystrophy (X-ALD). ABX-002 is a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential treatment of the adult-onset form of X-ALD, adrenomyeloneuropathy (AMN), a progressive and debilitating rare disease.

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced it has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma Inc. ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated prodrug conversion to enable delivery of small molecules across the blood brain barrier. Peripheral blockade of FAAH activity further improves selective brain delivery of Autobahn’s compounds and enhances the ability to tailor a drug’s biodistribution to match the pathophysiology of various disorders. ASP3652 may be developed in combination with multiple pipeline programs, including with Autobahn’s proprietary selective thyroid hormone receptor beta (TRβ) agonists for the treatment of multiple sclerosis (MS).

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the presentation of preclinical data of ABX-002, a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential treatment of adrenomyeloneuropathy (AMN), a progressive and debilitating rare disease. The data will be highlighted in a poster presentation at the American Academy of Neurology Annual Meeting, which is being held virtually from April 17-22, 2021. Posters will be made available at the start of the conference and remain viewable online through the virtual forum for 30 days after the meeting.